Clinical characteristics of patients with Susac syndrome at baseline and during follow-up
| Patient | Sex | Age (yr) | Clinical Symptoms at Onset of the Disease | No. of Relapses | Susac Criteria | Treatments during Follow-Up | Follow-Up Duration (mo) | ||
|---|---|---|---|---|---|---|---|---|---|
| Neurologic | Auditory | BRAO | |||||||
| 1 | F | 19 | Y | Y | Y | 0 | Definite | P, AVK, ASA, IVIG | 28 |
| 2 | F | 44 | Y | Y | N | 0 | Definite | ASA, IVIG | 53 |
| 3 | F | 43 | Y | N | Y | 7 | Definite | P, ASA, IVIG, CP | 46 |
| 4 | F | 32 | Y | N | Y | 1 | Definite | P, AVK, ASA, IVIG, CP, MM | 72 |
| 5 | F | 65 | Y | Y | Y | 2 | Definite | P, ASA, IVIG, CP | 37 |
| 6 | F | 29 | Y | Y | Y | 3 | Definite | P, ASA, IVIG, CP | 31 |
| 7 | F | 37 | Y | Y | Y | 0 | Definite | P, ASA, IVIG | 67 |
| 8 | M | 32 | N | N | Y | 1 | Probable | ASA, MM | 56 |
| 9 | F | 37 | Y | Y | Y | 3 | Definite | P, ASA, IVIG, CP, RTX | 1 |
Note:—Y indicates yes; N, no; BRAO, branch retinal artery occlusion; ASA, acetylsalicylic acid; AVK, anti-vitamin K; CP, cyclophosphamide; IVIG, intravenous immune globulin; MM, mycophenolate mofetil; P, prednisone; RTX, rituximab.